US00782.9112B2 (12) United States Patent (10) Patent No.: US 7,829,112 B2 ROn et al. (45) Date of Patent: Nov. 9, 2010 (54) METHODS AND DEVICES FOR THE 3,708,511 A 1/1973 Van Vliet et al. SUSTAINED RELEASE OF MULTIPLE 3,780,935 A 12/1973 Lukacs et al. DRUGS 3,880,759 A 4, 1975 Van Assendelft (75) Inventors: Eyal S. Ron, Lexington, MA (US); 3,892,664 A 7, 1975 Van Assendelft et al. Robert S. Langer, Newton, MA (US); 3,903,880 A 9/1975 Higuchi et al. William F. Crowley, Jr., Newtonville, MA (US) (73) Assignee: The General Hospital Corporation, (Continued) Boston, MA (US) FOREIGN PATENT DOCUMENTS (*) Notice: Subject to any disclaimer, the term of this EP O 121275 10, 1984 patent is extended or adjusted under 35 U.S.C. 154(b) by 186 days. (21) Appl. No.: 12/125,593 (Continued) (22) Filed: May 22, 2008 OTHER PUBLICATIONS (65) Prior Publication Data EP 0476 0436 (PCT/US2004/013172), Supplementary European US 2008/O286322 A1 Nov. 20, 2008 Search Report, issued Oct. 17, 2007 (5 pages). Related U.S. Application Data (Continued)Continued (62) Division- - - of application No. 10/835,414, filed on Apr. AssistantPrimary ExaminerExaminer RobertJeffrey A T. Wax Palenik 29, 2004. (74) Attorney, Agent, or Firm Nutter McClennen & Fish (60) Provisional application No. 60/466,318, filed on Apr. LLP 29, 2003, provisional application No. 60/473,579, filed on May 27, 2003. (57) ABSTRACT (51) Int. Cl. A6 IK9/00 (2006.01) The invention relates to an drug delivery device and a method A61 F6/08 (2006.01) for delivering multiple drugs over a prolonged period of time. (52) U.S. Cl. ....................................... 424/432: 514/843 The drug delivery device has two or more unitary segments (58) Field of Classification Search ....................... None comprising a drug-permeable polymeric Substance, wherein See application file for complete search history. at least one of the segments further comprises a pharmaceu tically active agent. The invention also relates to a method for (56) References Cited the treatment of a benign ovarian secretory disorder in a U.S. PATENT DOCUMENTS female mammal, a method of contraception, and a method of relieving the symptoms associated with menopausal, peri 3.454,004 A 7/1969 Spencer et al. menopausal and post-menopausal periods in a woman. 3,527,210 A 9, 1970 Towns 3,545,439 A 12/1970 Duncan 3,624,203 A 11/1971 Overbeek et al. 10 Claims, 9 Drawing Sheets 12 14 14 11 13 Y-0 US 7,829,112 B2 Page 2 U.S. PATENT DOCUMENTS 6,159,491 A 12/2000 Durrani 6,180,129 B1 1/2001 Magruder et al. 3,920,805. A 1 1/1975 Roseman 6,180,608 B1 1/2001 E. 3,938.515 A 2/1976 Leeper et al. 6,180,609 B1 1/2001 Garnicket al. 3,963,119 A 6, 1976 Lukacs et al. 6, 197,327 B1 3/2001 Harrison et al. 3,995,633. A 12/1976 Gougeon 6,217,893 B1 4/2001 Pellet et al. 3. A ; : Both 1 6,218,367 B1 4/2001 Jacob W. J. W. iguchi et al. D442,688 S 5, 2001 DeWeerdet al. 4,043,928 A 8, 1977 Lukacs et al. 6,264,973 B1 7/2001 Mahashabde et al. 1939. A E. High t al. 6.264,981 B1 7/2001 Zhang et al. W-1 - Oletal. 6,394,094 B1 5, 2002 McKenna et al. 4,096,860 A 6/1978 McLaughlin 6,416,779 B1 7/2002 DAugustine et al. 4,144.317 A 3/1979 Higuchi et al. 6,544.546 B1 4/2003 Groenewegen et al. 4,155,991 A * 5/1979 Schopflin et al. ............ 424/432 6,572,874 B1 6/2003 Harrison et al. 4,219.426 A 8/1980 Spekle et al. 6,905,701 B2 6/2005 Pauletti et al. E. A 3. St. al 2003/0049311 A1 3/2003 McAllister et al. aS Cla. 4,525,3404.484,599 A 11,6/1985 1984 LangeHanover et etal. al. FOREIGN PATENT DOCUMENTS 4,558,996 A 12/1985 Becker EP O 259 136 3, 1988 4.596,576 A * 6/1986 de Nijs ....................... 424/432 EP O 285 O57 10, 1988 4,629,449 A 12/1986 Wong EP O3O2 693 2, 1989 4,645,502 A 2f1987 Gale et al. EP O303 306 2, 1989 4,822,616 A 4, 1989 Zimmermann et al. EP O SO3 521 9, 1992 4,871.543 A 10/1989 Lindskog et al. EP 0 737 477 10, 1996 4,897,200 A 1/1990 Smakman et al. EP O 876 815 11, 1998 4,938,759 A 7, 1990 Enscore et al. EP O887074 A2 12/1998 4,957,119 A 9/1990 de Nijs et al. EP O 940 678 9, 1999 5,002,540 A 3, 1991 Brodman et al. EP 1 142959 10, 2001 5,088,505 A 2/1992 De Nijs et al. EP 1 221 315 T 2002 5,150,718 A 9/1992 De Nijs et al. JP O1-502265 T 8, 1989 5,211,952 A 5/1993 Spicer et al. JP 105.10168 T 10/1998 5,302,397 A 4, 1994 Amsden et al. JP 11-009699. A 1, 1999 5,324,523 A 6, 1994 ZSuga et al. JP 11-51296.5 T 11, 1999 5,340,584 A 8/1994 Spicer et al. JP 2002-513690 T 5, 2002 5,340,585 A 8, 1994 Pike et al. JP 2003507109 T 2, 2003 5,476,652 A 12/1995 Chinuki et al. WO 87/05514 9, 1987 5,482,706 A 1/1996 Igarietal. WO 89/O7959 9, 1989 5,543,150 A 8/1996 Bologna et al. WO 91,06290 5, 1991 5,593.965 A 1/1997 Lovas et al. WO 92/O5776 4f1992 5,601,839 A 2/1997 Quan et al. WO 92.16836 10, 1992 5,605,702 A 2f1997 Teillaudet al. WO 93,00058 1, 1993 5,681,568 A 10/1997 Goldin et al. WO 93,09765 5, 1993 5,725,852 A 3/1998 Igari et al. WO 95/O1979 1, 1995 5,738,864 A 4, 1998 Schacht et al. WO 95/05200 2, 1995 5,807,574 A 9, 1998 Cheskin et al. WO 95/33747 12/1995 5,834,010 A 1 1/1998 Quan et al. WO 96,0.1092 A1 1, 1996 5,840,685. A 1 1/1998 Fujii et al. WO 96,05315 2, 1996 5,855,906 A 1/1999 McClay et al. WO 96.31197 10, 1996 5,869,081 A 2, 1999 Jackanicz et al. WO 96.33678 10, 1996 5,919,478 A 7, 1999 Landrau et al. WO 96.34597 11, 1996 5,941,844 A 8, 1999 Eckenhoff WO 96.40.139 12/1996 5,945,123 A 8, 1999 Hermelin WO 97/O2O15 1, 1997 5,972,372 A 10, 1999 Saleh et al. WO 98.26788 6, 1998 5,985,861 A 11/1999 Levine et al. WO 98.39042 9, 1998 5,989,581 A 11/1999 Groenewegen et al. WO 99.24086 5, 1999 6,001,390 A 12/1999 Yum et al. WO 99.30976 6, 1999 6,013,276 A 1/2000 Math et al. WO 99.56934 11, 1999 6,013,853. A 1/2000 Athanasiou et al. 6,039,968 A 3/2000 Nabahi et al. WO OOOO158 1, 2000 6,068,909 A 5/2000 Koseki et al. WO OO/O1687 1, 2000 6,083,916 A 7/2000 Nonomura et al. WO OO,34255 6, 2000 6,086,909 A 7/2000 Harrison et al. WO OOf 41704 T 2000 6,103,256 A 8, 2000 Nabahi et al. WO OO,59512 10, 2000 6,113,938 A 9, 2000 Chen et al. WO OO.74742 12/2000 6,113,943 A 9, 2000 Okada et al. WO O1 13780 A2 3, 2001 6,126,958. A 10/2000 Saleh et al. WO 01,342.01 5, 2001 6,139,873 A 10/2000 Hughes, Jr. et al. WO O1/59 109 8, 2001 6,143,314. A 1 1/2000 Chandrashekar et al. WO O1,591.18 8, 2001 6,149,935 A 1 1/2000 Chiang et al. WO 01,64161 9, 2001 6,156,331 A 12/2000 Peery et al. WO 01f81408 11, 2001 6,159,490 A 12/2000 Deghenghi et al. WO O1/852.57 11, 2001 US 7,829,112 B2 Page 3 WO O2/34311 5, 2002 http://en.wikipedia.org/wiki/Torus, dated Dec. 9, 2009. WO 02040001 5, 2002 Glasier, Anna; Expert Opinion on Investigational Drugs (2002) OTHER PUBLICATIONS 11(9): 1239-1251. Roumen et al. Contraception, 59 (1) pp. 59-62 (1999). EP 0476 0436 (PCT/US2004/013172), Supplementary Partial Euro- iam pean Search Report, issued Aug. 20, 2007 (5 pages). Merriam-Webster Online Medical Dictionary; term searched: estro Bernkop-Schnurch et al., “Intravaginal Drug Delivery Systems'. Am. gen, dated Nov. 24, 2008. J. Drug Deliv, 1(4), pp. 241-254 (2003). www.caymanchem.com (see attached pdf for norgestrel and Johansson et al., “New Delivery Systems in Contraception: Vaginal ethynylestradiol), dated Feb. 4, 2009. Rings'. American Journal of Obstetrics and Gynecology, 190, s54-9 (2004). * cited by examiner U.S. Patent Nov. 9, 2010 Sheet 1 of 9 US 7,829,112 B2 12 14 14 11 13 Figure 1 U.S.